

ASX Announcement
24 July 2015

Business Update – Preliminary Indicative 30 June 2015 Guidance

- **Core business on track with ongoing growth trajectory**
- **Preliminary revenues for 30th June 2015, at \$33m, approximately 10% higher than FY2014**
- **Preliminary results indicate profitability in line with guidance, subject to audit, at \$1.8m to \$2.0m for NPAT and \$3.5 to \$4.0m for EBITDA (inclusive of medical innovation costs)**
- **Company expects growth trajectory to be maintained in FY2016**
- **Outlook strong with further opportunities to accelerate organic growth and value realisation**

Compumedics Limited (ASX: CMP) is pleased to announce, for the year ended 30th June 2015, preliminary results indicate the Company will generate increased profits in line with guidance provided, having shipped and invoiced approximately \$33m in sales. Final results will be subject to audit commencing in early August, with the Appendix 4E to be released to the Australian Stock Exchange (ASX) on August 26th.

The indicative results reflect the on-going positive outcomes from the Company's continuing process of renewing growth in key markets around the world as well as transforming and relocating key manufacturing activities to lower cost environments.

More detailed analysis and final results will be provided with the release of the Appendix 4E on August 26th.

About Compumedics Limited

Compumedics Limited (ASX: CMP) is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronische GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including Americas; Australia and Asia Pacific; and Europe and the Middle East.

Executive Chairman, Dr David Burton, founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised Sleep Clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets. Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards and accolades including Australia's exporter of the year and has been recognised as a Top 100 Innovator by the both German and Australian Governments.

For further information please contact:

Dr David Burton, Executive Chairman, CEO
Compumedics Limited
T: + 61 3 8420 7300, F: +61 3 8420 7399

Mr David Lawson, Executive Director, CFO
Compumedics Limited
T: + 61 3 8420 7300, F: +61 3 8420 7399

For investor relations and media enquiries please also contact:

Rod North, Managing Director,
Bourse Communications Pty Ltd
T: (03) 9510 8309, M: 0408 670 706
E: rod@boursecommunications.com.au